Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide informed consent, complete all study assessments and have complete medical record.~2. Age:18-75 years.~3. Histologically or cytologically confirmed diagnosis of local advanced or metastatic NSCLC.~4. Patients should be confirmed acquired EGFR T790M mutation and received osimertinib as the second line treatment, and they should have the following: (1) benefit from treatment with osimertinib initially ;(2) gradual progression on osimertinib treatment as defined by minor increment of tumor burden (≥10% but \<20% in the sum of target lesions).~5. At least one measurable lesion as defined by lesions ≥10mm in long axis according to RECIST 1.1.~Exclusion Criteria:~1. Patients who will be or were involved in any other interventional antitumour clinical studies for locally advanced/metastatic NSCLC currently or previously.~2. Small cell lung cancer (including small lung cancer mixed with non-small cell lung cancer).~3. Patients at risk of bleeding.~4. Patients with renal dysfunction.~5. Uncontrolled severe hypertension.~6. Any concomitant condition evaluated by physicians which is not suitable for osimertinib or anlotinib treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- osimertinib combined with anlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).